Држава: Малезија
Језик: Енглески
Извор: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
DORZOLAMIDE HCL
LOTUS HEALTHCARE MALAYSIA SDN. BHD.
DORZOLAMIDE HCL
1 x 5 ml mL
RAFARM S.A.
_Consumer Medication Information Leaflet (RiMUP) _ ____________________________________________________________________________ 1 LAMISOPT 20MG/ML EYE DROPS, SOLUTION Dorzolamide 20mg/ml WHAT IS IN THIS LEAFLET 1. What LAMISOPT is used for 2. How LAMISOPT works 3. Before you use LAMISOPT 4. How to use LAMISOPT 5. While you are using LAMISOPT 6. Side effects 7. Storage and disposal of LAMISOPT 8. Product description 9. Manufacturer and Product Registration Holder 10. Date of Revision WHAT LAMISOPT IS USED FOR LAMISOPT is prescribed to lower increased pressure in the eye and to treat glaucoma. This medicine can be used alone or in addition to other medicines which lower the pressure in the eye. HOW LAMISOPT WORKS LAMISOPT contains dorzolamide which belongs to a group of medicines called "carbonic anhydrase inhibitors". Dorzolamide inhibit production of aqueous humor in the eye, thus reduces high pressure in the eye. BEFORE YOU USE LAMISOPT _-_ _ _ _When you must not use it_ Do not take LAMISOPT: If you are allergic (hypersensitive) to dorzolamide hydrochloride or any of the other ingredients of LAMISOPT If you have severe kidney impairment, or a prior history of kidney stones If you are pregnant (or trying to become pregnant). If you are breastfeeding. If you have one of these conditions, do not take this medicine and inform your doctor. _-_ _ _ _Before you start to use it _ Before treatment with LAMISOPT eye drops, tell your doctor if you: have liver problems in the past have been told you have a corneal defect have any allergies to any medicines have, had or going to have eye surgery have suffered an eye injury or have an eye infection have a prior history of kidney stones are taking orally another carbonic anhydrase inhibitor wear contact lenses. If you have one of these conditions, INFORM YOUR DOCTOR. You doctor will take it into account during your treatment with LAMISOPT. _-_ _ _ _Taking other medicines _ _ _ Please tell your doctor or pharmacist if you are taki Прочитајте комплетан документ
LAMISOPT 20mg/ml EYE DROPS, SOLUTION DORZOLAMIDE CONTROLLED MEDICINE PRODUCT PARTICULARS 1. NAME OF PRODUCT LAMISOPT 20mg/ml EYE DROPS, SOLUTION 2. NAME AND STRENGTH OF ACTIVE INGREDIENT(S) Lamisopt 20mg/ml Eye Drops contain dorzolamide 20mg per ml, as dorzolamide Hydrochloride. 3. DOSAGE FORM Eye drops. 4. PRODUCT DESCRIPTION Lamisopt 20mg/ml Eye Drops is presented as slightly opalescent, nearly colourless, slightly viscous solution. 5.1. PHARMACODYNAMICS Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. Carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs) but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP). Lamisopt contains dorzolamide HCl, a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, Lamisopt reduces elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Unlike miotics, Lamisopt reduces intraocular pressure without the common side effects of miotics eg, night blindness, accommodative spasm and pupillary constriction. Unlike topical β -blockers, Lamisopt has minimal or no effect on pulse rate or blood pressure. Topically applied β -adrenergic-blocking agents also reduce IOP by decreasing aqueous humor secretion but by a different mechanism of action. When Lamisopt is added to a topical β -blocker, additional reduction in IOP is observed. 5.2. PHARMACOKINETICS Unlike oral carbonic anhydrase inhibitors, topical administration o Прочитајте комплетан документ